ExPEC4V
ExPEC4V, also known as JNJ-63871860, is a vaccine against urinary [tract infection]s and Escherichia coli infection. It is an Escherichia coli polysaccharide conjugate vaccine. The vaccine is administered by intramuscular injection. It is being developed by GlycoVaxyn and Johnson & Johnson. As of November 2023, ExPEC4V is in Phases of [clinical research#Phase II|phase 2] clinical trials. There is also a 10-valent form called ExPEC10V. In February 2025 Johnson & Johnson stopped the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.